Skip to main content
. 2020 May 20;117(23):13000–13011. doi: 10.1073/pnas.1917362117

Fig. 2.

Fig. 2.

Efficacy of hMGL-4.0 administration in murine PCa models. (A) Quantitation of tumor volume in male FVB/N mice bearing allograft tumors of HMVP2 PCa spheroids following treatment with hMGL-4.0 or controls (PBS, n = 17; hMGL-4.0 [50 mg/kg], n = 18). (B) Relative concentrations of l-Met and 2-ketobutyric acid in serum determined by MS following termination of the HMVP2 allograft studies (n = 5 per group). (C) Quantitation of tumor volume in male nude mice bearing xenograft tumors of DU145 PCa cells following treatment with hMGL-4.0 or controls (PBS, n = 9; heat-deactivated hMGL-4.0 [50 mg/kg], n = 15; hMGL-4.0 [50 mg/kg], n = 18). (D) Quantitation of tumor volume in male nude mice bearing xenograft tumors of 22Rv1 PCa cells following treatment with PBS, n = 12; hMGL-4.0 (50 mg/kg), n = 12; hMGL-4.0 (20 mg/kg), n = 12. Throughout, data are expressed as mean ± SEM. (A, C, and D) Repeated-measures two-way ANOVA followed by Bonferroni’s multiple-comparison test; (B) two-tailed Student’s t test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.